April 2017

Event Participation 2017

Banook Group will attend the following exhibitions. Let’s meet there!
Read the full post
February 2017

Cardiabase by Banook Group opens subsidiary in Montreal, Canada

Group strengthens its presence in North American market, aiming for 30% growth in…
Read the full post
May 2016

Webinar : ECG Assessment in Early Phase 1 Studies: How to get it right for possible TQT waiver?

Reserve your webinar seat now (limited number of places)   Click here :…
Read the full post
March 2015

Banook Group - New branding announcement

Cardiabase/Banook Central Imaging becomes Banook Group - New branding announcement.
Read the full post
March 2014

Webinar: Imaging anti-cancer treatment response at a preclinical and clinical stage

Use of imaging in oncology clinical trials is mainly based on morphological evaluation…
Read the full post
May 2016

Webinar : ECG Assessment in Early Phase 1 Studies: How to get it right for possible TQT waiver?

Reserve your webinar seat now (limited number of places)

 

Click here : https://attendee.gotowebinar.com/register/4388513019743906817


May 19th, 2016
5:00 PM CET (Central European Time) UTC/GMT +2 hours

 

Duration: 1 hour

 

Presented by:
Pierre Maison-Blanche - MD – Senior Advisor – Banook Group
Thierry Duvauchelle – MD - Clinical Pharmacologist – Phaster 1
Mathieu Felices - Pharmacometrician & Biostatistician - Phinc

Agenda:
Session #1
10 years from “ICH E14” to “ICH E14 Q&A (R3)”


The purpose of the presentation is first to assess the implementation IQT (intensive QT) study as an alternative to the TQT studies; then to assay sensitivity in IQT Studies.

Session #2
Implementation of “ICHE14 Q&A (R3)”


Taking into account that the priority is to generate guidance on concentration-response modelling, the exposure response as an alternative to IUT analysis will be assessed during this presentation as well as the usage of adequate modeling and definitions for a negative drug.

.